Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Inotek Pharmaceuticals Corp    ITEK

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

(d) Exhibits

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 09:26am CET

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive AgreementItem 1.01

Entry into a Material Definitive Agreement.

Exhibit No.

Description

2.1 Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1)
10.1 Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD
99.1 Press release of Inotek Pharmaceuticals Corporation dated September12, 2017
(1) Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment to Rule 24b-2 of the Exchange Act for any schedule so furnished.

* * *

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September13, 2017 INOTEK PHARMACEUTICALS CORPORATION
By:

/s/ Dale Ritter

Dale Ritter
Vice President – Finance

EXHIBIT INDEX

Exhibit No.

Description

2.1 Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1)
10.1 Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD
99.1 Press release of Inotek Pharmaceuticals Corporation dated September12, 2017
(1) Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment INOTEK PHARMACEUTICALS CORP ExhibitEX-2.1 2 d421363dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION       AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: INOTEK PHARMACEUTICALS CORPORATION,…To view the full exhibit click here
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

The post Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INOTEK PHARMACEUTICALS COR
11/02 INOTEK PHARMACEUTICALS CORP : Inotek Pharmaceuticals: Upcoming Merger with Rocke..
10/16 INOTEK PHARMACEUTICALS CORP : Today's Research Reports on Stocks to Watch: Inote..
10/16 INOTEK PHARMACEUTICALS : Announces Filing of Preliminary Proxy Statement for Pro..
10/12 INOTEK PHARMACEUTICALS CORPORATION ( : ITEK) Files An 8-K Financial Statements a..
10/12 INOTEK PHARMACEUTICALS CORP : Other Events, Financial Statements and Exhibits (f..
09/14 INOTEK PHARMACEUTICALS CORP : Today's Research Reports on Stocks to Watch: Inote..
09/14 INOTEK PHARMACEUTICALS CORPORATION ( : ITEK) Files An 8-K Entry into a Material ..
09/13 INOTEK PHARMACEUTICALS CORP : Entry into a Material Definitive Agreement, Unregi..
09/01 INOTEK PHARMACEUTICALS CORP : Change in Directors or Principal Officers, Financi..
08/10 INOTEK PHARMACEUTICALS : Patent Issued for Anhydrous Polymorphs of Methyl Nitrat..
More news
News from SeekingAlpha
10/13 After Hours Gainers / Losers
10/13 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
10/13 PREMARKET GAINERS AS OF 9 : 05 am
10/13 Inotek files proxy statement for proposed merger with Rocket Pharmaceuticals;..
10/06 After Hours Gainers / Losers
Financials ($)
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
David P. Southwell President, Chief Executive Officer & Director
J. Martin Carroll Chairman
Dale Ritter Secretary, Treasurer & Vice President-Finance
Rudolf A. Baumgartner Chief Medical Officer & Executive Vice President
Cadmus Collins Rich VP-Medical Affairs & Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
INOTEK PHARMACEUTICALS CORP68
GILEAD SCIENCES0.28%94 562
REGENERON PHARMACEUTICALS5.23%42 405
VERTEX PHARMACEUTICALS101.79%37 414
GENMAB-3.41%11 744
EXELIXIS, INC.66.00%7 642